Ikris Pharma Network Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ikris Pharma Network Private Limited Pharmaceutical Export Portfolio Dataset — 7 Products, $294.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ikris Pharma Network Private Limited — Pharmaceutical Exporter Profile (2026) | 7 Products, $294.4K Trade | TransData Nexus

Ikris Pharma Network Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $294.4K Total Trade · DGFT Verified

Ikris Pharma Network Private Limited is an Indian pharmaceutical exporter with a total trade value of $294.4K across 7 products in 2 therapeutic categories. Based on 217 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Actinomycin ($108.1K), Osimertinib ($76.3K), Ustekinumab ($50.0K).

Ikris Pharma Network Private Limited — Export Portfolio & Destination Treemap

Ikris Pharma Network Private Limited pharmaceutical export portfolio — 7 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ikris Pharma Network Private Limited? — Company Overview & Market Position

Ikris Pharma Network Private Limited is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on August 13, 2014, the company is registered under the Corporate Identification Number (CIN) U74120UP2014PTC065470. Its registered office is located at Unit No. 5, 9th Floor, Plot No. 40, Tower-A, Sector-62, Noida, Uttar Pradesh, India 201301.

The company is privately held, with authorized and paid-up capital of ₹15,00,000 each. As of the latest available data, Ikris Pharma Network employs between 11 to 50 individuals. Financially, the company reported operating revenue in the range of ₹10 to ₹25 crore for the fiscal year ending March 31, 2024, with a significant increase in EBITDA and net profit compared to the previous year.

What Does Ikris Pharma Network Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Actinomycin$108.1K 2Osimertinib

Product Portfolio — Top 7 by Export Value

Ikris Pharma Network Private Limited exports 7 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Actinomycin	Advanced Oncology	$108.1K	103	3.7%	3
2	Osimertinib	Advanced Oncology	$76.3K	17	7.0%	3
3	Ustekinumab	Biologics & Immunotherapy	$50.0K	36	3.9%	7
4	Tofacitinib	Advanced Oncology	$21.1K	14	0.5%	8
5	Lapatinib	Advanced Oncology	$20.0K	3	0.4%	5
6	Procarbazine	Advanced Oncology	$13.9K	22	5.3%	3
7	Lomustine	Advanced Oncology	$4.9K	22	4.8%	5

Ikris Pharma Network Private Limited exports 7 pharmaceutical products across 2 therapeutic categories with a total export value of $294.4K. The top category is Advanced Oncology (83.0% of portfolio), followed by Biologics & Immunotherapy (17.0%), indicating a concentrated portfolio with the top 5 products accounting for 93.6% of total export value.

Ikris Pharma Network Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Ikris Pharma Network's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's product portfolio comprises finished pharmaceutical formulations, indicating that manufacturing is likely conducted in-house or through contract manufacturing arrangements. However, without explicit information, a comprehensive assessment of their manufacturing capabilities cannot be provided.

3Key Leadership

Ikris Pharma Network Private Limited is led by two directors:

Parveen Sikri: Appointed on August 13, 2014.

Bharat Sikri: Also appointed on August 13, 2014.

Detailed information regarding other key executives, such as the CEO, CFO, and their specific roles, is not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ikris Pharma Network Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ikris Pharma Network's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly documented in the available sources. The company's export data indicates shipments to various countries, but specific regulatory approvals or market access statuses in these regions are not detailed. Without explicit information, a comprehensive analysis of their regulatory standing in these markets cannot be provided.

2Emerging Markets

Ikris Pharma Network has engaged in export activities to emerging markets, including countries in Africa, Latin America, and Southeast Asia. The company's export data highlights shipments to regions such as Portugal, Fiji, and Equatorial Guinea. However, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available.

3Geographic Strategy

Ikris Pharma Network's export activities demonstrate a focus on both established and emerging markets. The company's portfolio concentration, with the top five products accounting for 93.6% of total export value, suggests a strategic emphasis on a select range of products. However, without detailed information on their geographic diversification strategy, a comprehensive assessment of concentration risk and strategic direction cannot be provided.

Ikris Pharma Network Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Ikris Pharma Network's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history is not publicly available. Without explicit data, a detailed analysis of their FDA status cannot be conducted.

2WHO & EU GMP

There is no publicly available information indicating that Ikris Pharma Network holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. Without explicit details, an assessment of their compliance with these standards cannot be provided.

3CDSCO & Indian Regulatory

Specific details regarding Ikris Pharma Network's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly disclosed. Without explicit information, a comprehensive analysis of their regulatory standing within India cannot be conducted.

Ikris Pharma Network Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ikris Pharma Network operates in the competitive pharmaceutical export sector, focusing on finished pharmaceutical formulations. While specific competitors are not identified in the available data, the company's export activities to various countries suggest competition with other pharmaceutical exporters targeting similar markets. A detailed market share comparison and head-to-head analysis would require access to proprietary market research data.

2Key Differentiators

Ikris Pharma Network's key differentiators include its specialization in finished pharmaceutical formulations and its focus on both established and emerging markets. The company's portfolio concentration indicates a strategic emphasis on a select range of products, potentially allowing for specialized expertise and operational efficiencies. However, without detailed information on their product development capabilities and market positioning, a comprehensive assessment of their competitive advantages cannot be provided.

3Strategic Position

Ikris Pharma Network's strategic direction appears to involve a focus on finished pharmaceutical formulations, with a portfolio concentrated on a select range of products. The company's export activities to various countries suggest a strategy that includes both established and emerging markets. However, without explicit information on their future outlook, including plans for generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, a comprehensive assessment of their strategic position cannot be provided.

Buyer Due Diligence Brief — Evaluating Ikris Pharma Network Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ikris Pharma Network's track record in terms of export volume and consistency is demonstrated by its 217 shipments totaling $294,000 USD in export value. The company's portfolio concentration, with the top five products accounting for 93.6% of total export value, suggests a focused approach to product offerings. However, without detailed information on their supply chain reliability and consistency, a comprehensive assessment of their supplier performance cannot be provided.

2Certifications to Verify

Importers considering partnerships with Ikris Pharma Network should verify the following certifications:

FDA Registration: Confirm the company's FDA facility registration status to ensure compliance with U.S. regulatory standards.

WHO-GMP Certification: Verify the company's compliance with World Health Organization Good Manufacturing Practice standards.

Frequently Asked Questions — Ikris Pharma Network Private Limited

How many pharmaceutical products does Ikris Pharma Network Private Limited export from India?

Ikris Pharma Network Private Limited exports 7 pharmaceutical products across 2 therapeutic categories. The top exports are Actinomycin ($108.1K), Osimertinib ($76.3K), Ustekinumab ($50.0K), Tofacitinib ($21.1K), Lapatinib ($20.0K). Total export value is $294.4K.

What is Ikris Pharma Network Private Limited's total pharmaceutical export value?

Ikris Pharma Network Private Limited's total pharmaceutical export value is $294.4K, based on 217 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ikris Pharma Network Private Limited cover?

Ikris Pharma Network Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (83.0%, 6 products), Biologics & Immunotherapy (17.0%, 1 products).

Get Full Ikris Pharma Network Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.